NIPT Prenatal Screen by Biomnis
The discovery of foetal DNA in maternal blood, combined with a new and very high-output sequencing method (NGS - Next-Generation Sequencing) has opened numerous perspectives in the field of non-invasive prenatal testing (NIPT). One of the principal applications of this method is the screening of the main foetal aneuploidies i.e trisomy 21, 18 and 13 and thanks to this innovative new technology, a simple blood sample is now sufficient to perform genetic testing for trisomy 21, 18 & 13, ensuing no risk for the foetus while remaining highly reliable.
Download the full PDF from here.